The FDA approves brentuximab vedotin (Adcetris) for certain types of CTCL

The FDA approves the use of brentuximab vedotin (Adcetris) treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF). More >

Image: